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Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative 
therapies. The European Union (EU) and the United States (US) are fostering their 
development. For both regions, ATMPs fall under the regulatory framework of biological 
products, which determines the legal basis for their development. Sub-classifications 
of advanced therapies are different between regions, while in EU, there are four major 
groups, i.e., gene therapy, somatic cell therapy, tissue-engineered therapies, and 
combined advanced therapies; in US, the sub-classification covers two major groups of 
products, i.e., gene therapy and cellular therapy. The inclusion criteria that define a gene 
therapy are equivalent in both regions, and the exclusion criteria are directly related to 
the indications of the product. In the EU, there is a clear differentiation between cell- and 
tissue-based products regarding their classification as advanced therapies or coverage 
by other legal frameworks, whereas in US, there is a broader classification about whether 
or not these products can be categorized as biologic products. Both in EU and in US, 
in order to classify a cell- or a tissue-based product as an advanced therapy, it must be 
ensured that the processing of the cells implies a manipulation that alters their biological 
characteristics, although the term of manipulation in US differentiates between structural 
and non-structural cells and tissues. The regulatory terminology used to define ATMPs 
and their sub-classification reveals some differences between EU and US.
Keywords: genetic therapy, tissue engineering, cell- and tissue-based therapy, biological products, biological 
therapy, legislation and jurisprudence, United States Food and Drug Administration, Europe
INTRODUCTION
Advanced therapy medicinal products (ATMPs) comprise a category of innovative and complex 
biological products, which in most cases require extensive and complicated preclinical and clinical 
developments. This complexity has been observed since the idea of transferring genetic material to 
cure a genetic disease was foreseen decades ago. The first ATMP product approved in the European 
Union (EU) came in 2009 with the authorization of ChondroCelect®, a tissue-engineered product 
indicated for the treatment of cartilage defects (European Medicines Agency, 2017a). In United 
States (US), the first approved ATMP came out 1 year later with PROVENGE®, a somatic cell therapy 
for the treatment of some prostate cancers (U.S. Food and Drug Administration, 2019a). The first 
authorized gene therapy was launched in 2012, when Glybera® achieved marketing authorization in 
EU (European Medicines Agency, 2012).
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The delay between the theoretical concept of an ATMP and 
the first clinical trials that lead to a new treatment approval may 
be due to the multiple challenges that arise from the nature of 
ATMPs, including not only scientific and technical challenges 
but also regulatory ones (Ten Ham et al., 2018). The first step 
in their development is the definition of the product, and 
consequently, its classification. In both in EU and the US, there 
is a broad legal framework, ranging from medicinal products 
consisting of chemical substances to biological substances; the 
latter of which includes a wide range of possible products. In this 
sense, the classification of a potential biological product is often 
not so trivial, and in some cases, it may be difficult to discern 
the line between different biological subcategories. The correct 
classification of a product at an early stage of development is a 
critical point, since it will determine the regulatory framework 
and the European and American recommendations to follow 
throughout the whole development plan of the product in 
each region.
This article aims to review the legal frameworks in the EU 
and US for ATMPs, as well as the criteria to be met to define 
a product as such. The similarities and differences that exist 
between both regions are discussed in order to identify those 
nuances that may affect the development of an ATMP. A specific 
search for official regulatory documents concerning medicinal 
products for human use with a specific focus on ATMPs, such 
as legislation, guidelines, presentations, and reports, from the 
websites of the European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) competent authorities was 
carried out until 31st December 2018. Key terms that covered the 
regulatory framework for advanced therapies and other products 
were used to navigate the websites of these competent authorities, 
including: terms describing advanced therapies (advanced 
therapy, advanced therapies, regenerative medicine, cell therapy, 
cell-based therapy, human cellular therapy, stem cells, gene 
therapy, tissue engineering, human cell therapy, human somatic 
cell therapy), information on the regulatory framework, and the 
definition and classification of advanced therapies in EU and US.
REGULATORY FRAMEWORK FOR 
THE CLASSIFICATION OF ADVANCED 
THERAPIES
Medicinal products for human use in EU are governed by 
Directive 2001/83/EC and Regulation 726/2004/EC. Biological 
products comprise many diverse product types, including 
immunological medicinal products (i.e., vaccines, toxins, 
serums, and allergens), medicinal products derived from human 
blood and human plasma (i.e., albumin, coagulation factors, and 
immunoglobulins of human origin), biotechnology products 
such as antibodies, and ATMPs, which are the focus of this 
paper (European Union, 2003a). ATMPs consist of products 
that contain recombinant nucleic acids or engineered cells and/
or tissues. These products are divided into four subcategories: 
somatic cell therapy medicinal products (SCTMP), tissue-
engineered products (TEP), gene therapy medicinal products 
(GTMP), and the combined ATMPs (cATMPs). These last ones 
consist of one of the first three categories combined with one or 
more medical devices as an integral part of the product (European 
Union, 2007). In EU, there is a clear differentiation between cell-
based products considered as advanced therapies, and cell-based 
therapies covered by other legal frameworks such as the blood 
system or transplant laws, where these cells are not considered 
a medicinal product, and the active substance, i.e., human cells 
and tissues, cannot be commercialized or manufactured on an 
industrial scale for ethical and legal reasons (European Union, 
2003b; European Union, 2004; European Union, 2010). The 
classification of an ATMP as a biological product will determine 
the wider regulatory framework by which the requirements of 
the development and the marketing authorization application 
are defined. These are to be read in conjunction with the specific 
framework for ATMPs, Regulation 1394/2007/EC, which came 
into force on December 30, 2008. This regulation provides the 
overall framework on ATMPs for those products, which are 
intended to be placed in the market of EU Member States. In 
addition, Directive 2009/120/EC updated the definitions and 
detailed scientific and technical requirements for advanced 
therapies. The cATMPs are not only regulated under the 
guidelines of medicinal products but also of medical devices. On 
25 May 2017, two new regulations on medical devices came into 
force (European Commission, 2017a).
For the development of advanced therapies in EU, the clinical 
trial applications are submitted individually to the national 
competent authorities where the trial will take place. However, 
for the marketing authorization, all ATMPs are evaluated via 
centralized procedure ensuring that they benefit from a single 
evaluation and authorization applicable across the EU. There 
are two committees responsible for the validation and scientific 
evaluation for product approval: the Committee for Advanced 
Therapies (CAT) and the Committee for Medicinal Products for 
Human Use (CHMP) (European Medicines Agency, 2018a). The 
CAT is the EMA committee responsible for classifying; assessing 
the quality, safety, and efficacy of ATMPs; and following scientific 
progress in the field. This committee’s main responsibility is to 
prepare a draft opinion on each ATMP application submitted to 
the EMA in order to support the final decision by the CHMP. 
This marketing authorization via the centralized procedure may 
be granted in three ways: standard marketing authorization, 
conditional marketing authorization (when an innovative medicine 
addresses an unmet medical need yet a positive benefit-risk 
balance by sufficient clinical data is demonstrated), and marketing 
authorization under exceptional circumstances in those extreme 
situations where a disease is rare or a clinical endpoint is difficult 
to measure (Detela and Lodge, 2019). Regarding classification, the 
CAT offers the confirmation that a medicine meets the scientific 
criteria to be classified as an ATMP. On the other hand, the 
regulatory authority in charge of medical devices is the national 
appointed bodies of each EU member. In the case of cATMP, the 
CAT interacts with the notified bodies in order to prepare the draft 
opinion on a cATMP (European Medicines Agency, 2011a).
In US, like in EU, advanced therapies are regulated as biologic 
products. In legislative terms, biological products comprise the 
following categories: i) the group of allergenics that includes 
allergen extracts, allergen patch tests, and antigen skin tests; 
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ii)  blood and blood products, iii) vaccines, iv) xenotrasplants, 
and v) cellular and gene therapy products (CGTs), which 
constitutes the group of advanced therapies and encompasses 
two sub-categories of products. Advanced therapies should not 
be confused with other legislative category of products called 
“human cells, tissues, and cellular and tissue-based products” 
(HCT/Ps) and defined as “articles containing or consisting of 
human cells or tissues intended for implantation, transplantation, 
infusion, or transfer into a human recipient” (U.S. Food and Drug 
Administration, 2019). HCT/Ps are not considered biological 
products. On the other hand, combination products include 
products that are comprised of two or more regulated components, 
i.e., drug/device, biologic/device, drug/biologic, or drug/device/
biologic. The definition is broad and takes into account the 
packaging and whether all components of the product are needed 
to achieve the intended use, indication, or effect (U.S. Food and 
Drug Administration, 2018a). In 2016, the 21st Century Cures 
Act (Cures Act) was signed into law in order to help accelerate 
medicinal product development and bring new therapies to the 
market faster and more efficiently. This Act established a new 
expedited product development program called the Regenerative 
Medicine Advanced Therapy (RMAT) (U.S. Food and Drug 
Administration, 2018b). Although it is not a type classification 
per se, yet a designation that offers a new expedited option for 
evaluation of the product, it is considered worth mentioning 
it here as a part of the US advance therapy classification. A 
regenerative medicine therapy is defined as: i) a cell therapy, 
therapeutic tissue-engineering product, human cell and tissue 
product, or any combination product using such therapies or 
products, explicitly excluding HCT/Ps; ii) that is intended to treat, 
modify, reverse, or cure a serious or life-threatening disease or 
condition; and iii) if the preliminary clinical evidence indicates 
that the drug has the potential to address unmet medical needs for 
such disease or condition (U.S. Food and Drug Administration, 
2019b). Therefore, this definition implicitly includes advanced 
therapy medicinal products. A combination product can also 
be eligible for RMAT designation when the biological product 
component provides the primary mode of action. These products 
would be denominated as RMAT-based combination products. 
More than 30 out of 90 RMAT designation requests have been 
granted until 2019 (U.S. Food and Drug Administration, 2019c).
The US federal regulatory framework consists of two main 
statutes, Federal Food, Drug, and Cosmetic Act (FDCA) and the 
Public Health Services Act (PHSA), which provide the Food and 
Drug Administration (FDA, the federal regulatory medicines 
agency in the US) with the legal authority to regulate human 
medicinal products including drugs, biological products, and 
devices. Biological products, and therefore advanced therapies, 
are regulated under section 351 of the PHSA and under the 
FDCA, because most biological products also meet the definition 
of “drugs” cited in this Act. FDA regulations are contained in the 
Code of Federal Regulations (CFR), which provides details on 
how the FDA implements the activities that are defined in the 
PHSA and FDCA. Regulations for biological and medical devices 
are found in Title 21 of the CFR (Lee et al., 2015; U.S. Title 42 
The Public Health and Welfare, 2019). In US, the applicants 
need to submit an investigational new drug (IND) application 
in order to obtain a clinical trial approval (U.S. Food and Drug 
Administration, 2017a), and Biologics License Application 
(BLA) to obtain a marketing authorization (U.S. Food and 
Drug Administration, 2018c). The marketing authorization can 
be standard, under a Priority Review procedure or under an 
Accelerated Approval. In the Priority Review, the application 
is reviewed within 6 months compared to 10 months under 
standard review, and it is addressed to those drugs that, if 
approved, would bring about significant improvements in the 
safety or effectiveness of the treatment, diagnosis, or prevention 
of serious conditions when compared to standard applications. 
An Accelerated Approval allows drugs for serious conditions that 
filled an unmet medical need to be approved based on a surrogate 
endpoint, if clinical benefit has been demonstrated (U.S. Food 
and Drug Administration, 2018d).
Within the FDA, responsibilities for drugs, biologic products 
and devices are organized in eight different centers. The Centre 
for Biologics Evaluation and Research (CBER) has jurisdiction 
over a variety of biological products, including blood and blood 
products, vaccines and allergenic products, and cellular, tissue, 
and gene therapies, as well as some related devices. Within the 
CBER, the responsibility for advanced therapies falls to the Office 
of Tissues and Advanced Therapies (OTAT), formerly known as 
Office of Cellular, Tissue, and Gene Therapies (OCTGT). OTAT 
comprises five divisions in addition to the Office of the Director 
(U.S. Food and Drug Administration, 2017b). Combination 
products are assigned to a FDA center that will have primary 
jurisdiction for its pre-market review and regulation. For 
combination products, CBER usually regulates medical devices 
related to licensed blood and cellular products by applying 
appropriate medical device laws and regulations (U.S. Food and 
Drug Administration, 2018e). This assignment is performed 
by the Office of Combination Products through a designation 
process (U.S. Food and Drug Administration, 2018f).
The current European and American legislations for biological 
products are summarized in Table 1. One of the main differences 
between EU and US is that the FDA oversees clinical trials, whereas 
the EMA does not. In terms of marketing approval, each region 
has specific legislations depending on the legal categorization of 
the product; in EU, they are licensed under article 8.3 of Directive 
2001/83/EC, while in US, ATMPs are licensed under section 
351 of the PHS Act. Both Agencies have their own specialized 
committees to evaluate advanced therapies. In US, the approval 
time for a standard BLA may extend up to 10 months from 
receipt date (U.S. Food and Drug Administration 2017c), while 
in EU, the assessment leads to an opinion from the CHMP by day 
210 and European Commission by day 277 (around 7 months) 
(European Medicines Agency, 2016b). However, these timelines 
depend on the different types of marketing authorization 
available in each region. Among advanced therapies, product 
sub-classifications are slightly different between regions. While 
in the EU, an ATMP can be sub-classified into four major 
groups, i.e., GTMP, SCTMP, TEP, or cATMP, in the US the 
sub-classification groups are broader, covering two groups of 
products, i.e., gene therapy and cellular therapy products. Given 
that the sub-classification in the EU is more precise, there are 
products that could fall into two categories, and in some cases, 
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the assignment in a particular subtype is not so trivial. In the case 
of US, the difficulty might arise when classifying the product as 
an HCT/Ps or as a biological product that falls beyond minimal 
manipulation and/or homologous use. Finally, another difference 
between regions is related with terminology; in the US, the term 
“advanced therapy” is not a common term used in legislative 
and regulatory documents, and these products are collectively 
referred as “CGT products.”
To ensure a correct classification, both the EMA and the FDA 
have made scientific advice available to the applicants to clarify 
or corroborate this classification prior to further advancing the 
development. In EU, one of CAT’s activities is to clarify the 
classification of a given product, above all when the product 
could fall in two different categories (European Medicines 
Agency, 2013a). It is always advisable to obtain CAT’s opinion 
about a particular product, since the features of each product can 
be unique, and the corroboration of a product as an advanced 
therapy might add value to attract potential investors. On the 
other hand, in US, the Tissue Reference Group is the working 
group within the FDA that provides recommendations to 
stakeholders concerning the application of the criteria for HCT/
Ps. For both consultations, a minimum of information on the 
product is required in order to obtain its proper classification, 
such as the source of the product, the intended use of the 
product, or description of how the product is processed from the 
time of recovery to the point of use of step-by-step (U.S. Food 
and Drug Administration, 2018g). Another consultation option 
at an early stage of development is to hold informal meetings 
with the Agencies in order to obtain informal exchange of 
information and receive advice and recommendations on the 
development process in terms of scientific, regulatory, and legal 
issues. For complex products, this type of meeting might also be 
helpful in order to obtain the first legal and scientific feedback 
on the classification of the product. For EU, these meetings are 
called Innovation Task Force (ITF) briefing meetings (European 
Medicines Agency, 2013a), while the equivalent meeting in US 
is called Initial Targeted Engagement for Regulatory Advice 
(INTERACT) meetings (U.S. Food and Drug Administration, 
2018h). The ATMP classification procedures are valuable to 
address questions on borderline classifications, commonly 
raised for combined ATMPs, to confirm the medicinal product 
framework and determine what type of ATMP a product is, 
and therefore, develop the product under the specific dossier 
requirements and quality guidances.
Finally, it is worth noting that the main EU and US Agencies 
have launched expedited development programs in order to 
enable new medicines reach the market as early as possible. The 
medicines that are eligible to these programs are those that can 
justify a potential major public health interest, i.e., they target 
conditions where there is an unmet medical need or have the 
potential to bring a major therapeutic advantage to patients. 
Since ATMPs usually offer new treatments for currently incurable 
conditions or improve existing treatments, most ATMP are 
eligible to these types of accelerated programs. The FDA has 
developed the Breakthrough Therapy and Fast Track designation 
programs (U.S. Food and Drug Administration, 2018d), while the 
EU launched the adaptive licensing and afterwards the PRIority 
Medicines (PRIME) designation scheme. The difference between 
the Breakthrough Therapy and Fast Track designations falls on 
the qualifying criteria for the designation. In the latter, clinical 
or nonclinical data should demonstrate potential to address 
an unmet medical need, whereas in the former, preliminary 
clinical evidence indicates that it may demonstrate substantial 
improvement over available therapies on a clinically significant 
endpoint(s). The EU PRIME and the US Breakthrough Therapy 
designations share the same objective (timely patient access to 
innovative medicines) but have a different legal basis; hence, 
comparison and harmonization are difficult. However, since late 
2016, FDA and EMA have worked together to track submitted 
requests for PRIME and Breakthrough Therapy designations and 
compare final review outcomes, including specific reasons for a 
designation request denial (European Medicines Agency, 2018b). 
TABLE 1 | Legal and regulatory framework of biological products in United States and European Union.
European Union United States
Type of product Legal framework Regulatory organism Type of 
product
Legal framework Regulatory 
organism
Advanced therapy 
medicinal products:
Gene therapy 
products
Cell therapy products
Tissue-engineered 
products
Directive 2001/83/EC (relating to medicinal 
products for human use)
Directive 2009/120/EC (relating to medicinal 
products for human use as regards 
advanced therapy medicinal products)
Regulation 726/2004/EC (community 
procedures for the authorization and 
supervision of medicinal products for human 
and veterinary use and establishing a 
European Medicines Agency)
Regulation 1394/2007/EC (on advanced 
therapy medicinal products and amending 
Directive 2001/83/EC and Regulation (EC) 
No 726/2004)
Clinical trials are under 
national competent 
authorities of each 
member state where 
the clinical trial will take 
place. 
Product positive 
opinion: CHMP
Draft opinion: CAT
Human 
somatic cell 
therapy and 
gene therapy 
products
Section 351 of the PHSA 
and FDCA and Title 21 CFR 
600-680 (Regulation on 
Biologics)
(21 CFR 1271; prevent 
the spread of infection 
diseases)
RMAT designation: section 
3033 of the 21st Century 
Cures Act (21 U.S.C. 356[g] 
(8))
CBER and 
OTAT
CAT, Committee for Advanced Therapies; CBER, Centre for Biologics Evaluation and Research; CHMP, Committee for Human Medicinal Products; FDCA, Federal Food, Drug, and 
Cosmetic Act; OTAT, Office of Tissues and Advanced Therapies; PHSA, Public Health Services Act; RMAT, Regenerative Medicine Advanced Therapy Designation.
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Throughout 2019, a database utilizing publicly available and 
company provided information to create a public list of RMAT 
recipients, as well as other expedited approval designations 
awarded in the US, EU, and Japan, is foreseen to be launched 
(Regulatory Affairs Professional Society, 2019).
CLASSIFICATION CRITERIA IN EUROPE 
AND UNITED STATES
Gene Therapies
Some examples of gene therapy products include in vivo therapies, 
such as nucleic acids or genetically modified microorganisms 
(e.g., viruses, bacteria, fungi), and ex vivo therapies like 
genetically modified human cells or human genome editing. In 
the EU, in order to classify a product as a gene therapy, all of the 
following inclusion criteria must be met (European Medicines 
Agency, 2015): i) the product has to be a biological medicinal 
product according to Directive 2003/63/CE; ii) the product must 
contain recombinant nucleic acid(s); iii) the recombinant nucleic 
acids should be of biological origin, regardless of the origin of 
the vector system used; iv) the recombinant nucleic acid is used 
in or administered to human beings in order to regulate, repair, 
replace, add, or delete a genetic sequence; and v) the recombinant 
nucleic acid(s) should be directly involved in the therapeutic, 
prophylactic, or diagnostic effect of the product (Table 2). It 
should also be noted that, according to the ATMP Regulation 
(European Union, 2007), a product that may fall within the 
definition of a SCTMP or a TEP, and a GTMP, shall be considered 
a GTMP, since it is the one that can pose the most safety concerns.
In the US, the inclusion criteria that must be met are the 
following (U.S. Department of Health and Human Services, 
1993; U.S. Department of Health and Human Services, 1998): i) 
the product meets the definition of “biological product” in 
section 351(i) of the PHSA [42 U.S.C. 262(i)]; ii) the product 
has to be applicable to the prevention, treatment, or cure of a 
disease or condition of human beings; iii) the product mediates 
its effects by transcription or translation of transferred genetic 
material or by specifically altering host (human) genetic 
sequences; and iv) the product can work through several 
mechanisms: replacing a disease-causing gene with a healthy 
copy of the gene, inactivating a disease-causing gene that is not 
functioning properly, or introducing a new or modified gene 
into the body. Recombinant DNA materials used to transfer 
genetic material for such therapy are considered components of 
gene therapy (Table 3).
Therefore, despite the different terminology used, the inclusion 
criteria that define a GTMP are equivalent in both regions: the 
product must be a biological product that contains “recombinant 
nucleic acid(s)” (term used in EU) or “genetic material” (term 
used in US), which through its action mechanism prompts the 
desired primary effect: addition, manipulation, or modification 
of gene expressions on human beings. Two autologous chimeric 
antigen receptor (CAR) T-cell therapies (Kymriah® and Yescarta®) 
were recently approved by the EMA and the FDA. These therapies 
are classified as cell-based gene therapies in both regions since 
they consist of genetically modified T cells expressing a CD19-
specific CAR in order to lyse CD19-positive targets (normal and 
malignant B lineage cells). The fact that the product has to be a 
biological medicinal product is not a minor inclusion criterion, 
since chemically synthesized nucleic acid sequences will be 
excluded from being classified as ATMPs and will be considered 
chemical drugs that should be developed under another legal 
framework—as for example, antisense oligonucleotides and 
aptamers approved by the EMA and FDA as chemical drugs. Unlike 
the US, in EU, one of the inclusion criteria for GTMP establishes 
that the recombinant nucleic acids should be of biological origin, 
regardless of the origin of the vector system used. On the other 
hand, in both regions, the product has to be applicable to the 
prevention and treatment of a human disease. However, diagnosis 
is neither cited as one of the primary goals of these products in the 
US nor does the US definition of a biologic product, according to 
the PHSA Act, contemplates diagnosis as a purpose of the product 
(U.S. Title 42 The Public Health and Welfare, 2019). In EU, there 
is one exclusion criterion that explicitly vetoed a product from 
being classified as a gene therapy: those products aimed at the 
treatment or prophylaxis of infectious diseases. These products 
would be classified as vaccines, even if the product meets all of 
the necessary criteria to be considered an advanced therapy 
(European Medicines Agency, 2015). For instance, a modified 
vaccinia virus ankara (MVA) into which two genes have been 
placed for the treatment of non-small cell lung cancer is classified 
as a GTMP, but if these genes lead to foreign protein expression 
for the treatment of human immunodeficiency virus (HIV) 
disease, the product will not be considered an advanced therapy, 
but a vaccine (European Medicines Agency, 2016b; Draper and 
Heeney, 2010). The same principle applies to non-viral vectored 
products such as most plasmid DNA- or RNA-based products. 
For instance, Trimix is a mixture of mRNAs encoding for antigen 
presenting cell activation molecules. If this mixture of mRNAs 
is combined with tumor-associated antigens for the treatment 
of melanoma, the therapy is classified as a GTMP, but if these 
mRNA are combined with mRNA encoding for HIV antigens, 
the therapy will be considered a vaccine (European Medicines 
Agency, 2016b). In the US, it is not specifically mentioned as an 
exclusion criterion, but prophylaxis or therapeutic vaccines for 
infectious diseases have their own guidances for development, 
and these products are typically reviewed by the CBER/Office of 
Vaccines Research and Review (OVRR) and not by the OTAT (U.S. 
Department of Health and Human Services, 2007). Therefore, the 
criterion for excluding a product from being classified as a GTMP 
in both regions is directly related to the indications of the product. 
Although some regulatory and development requirements for 
both types of products overlap, since these vaccines may be gene-
based, for either region, there are guidelines specifically addressed 
to the development of vaccines or gene therapy products 
independently. A consequence of this classification is that some 
of the available EU regulatory procedures that facilitate the 
development of ATMPs would not apply in the case of products 
classified as vaccines; for instance, the possibility of certifying the 
quality and non-clinical data for ATMP applications by the EMA 
(European Medicines Agency, 2010).
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Cell and Tissue Therapies
In the EU, SCTMP are distinguished from TEP. However, 
both class products share the same inclusion principle, i.e., the 
cells or tissues of the product must be “engineered,” and the 
difference lays in the indication. To consider a cell or tissue as 
“engineered,” it must fulfill at least one of the following criteria 
(European Union, 2007): i) the cells or tissues have been subject 
to substantial manipulation, or ii) the cells or tissues are not 
intended to be used for the same essential function(s) in the 
recipient and the donor, i.e., non-homologous use. Regarding the 
indication, in the case of SCTMP, the product is administered to 
human beings with a view to treating, preventing, or diagnosing 
a disease through the pharmacological, immunological, or 
metabolic actions of its cells or tissues, whereas in the case 
TABLE 2 | Inclusion/exclusion criteria in European Union.
Advanced Therapy medicinal products
Product category Active substance Purpose Inclusions Exclusions 
Gene therapy 
medicinal 
products 
(GTMPs)
Recombinant nucleic acid of 
biological origin
Administered to human beings 
with a view to regulating, 
repairing, replacing, adding, or 
deleting a genetic sequence 
Therapeutic, prophylactic, or 
diagnostic effects that relate 
directly to the recombinant 
nucleic acid sequence it 
contains, or to the product 
of genetic expression of this 
sequence
• Plasmids DNA 
• Viral vectors
• Genetically engineered 
microorganisms
• Human gene–editing 
technology
• Patient-derived cellular gene 
therapy products
• Non-biological products (e.g., 
chemical synthetized nucleic 
acids)
• Vaccines against infectious 
diseases
Somatic 
cell therapy 
medicinal 
products 
(SCTMPs)
Cells or tissues that have 
been subject to substantial 
manipulation or not intended to 
be used for the same essential 
function(s) in the recipient and 
the donor
Treating, preventing, or 
diagnosing a disease 
through the pharmacological, 
immunological, or metabolic 
actions of its cells or tissues
• Products containing or 
consisting of animal cells or 
tissues
• Cancer immunotherapies
• Other autologous and 
allogeneic cells therapies
• Xenogeneic living cells
• Stem cells and stem cell–
derived products
• Products containing or 
consisting exclusively of 
non-viable cells or tissues 
and which do not act 
principally by pharmacological, 
immunological, or metabolic 
actions
Tissue-
engineered 
products (TEP)
Cells or tissues that have 
been subject to substantial 
manipulation or not intended to 
be used for the same essential 
function(s) in the recipient and 
the donor
The cells or tissues may be 
viable or non-viable. 
Regenerating, repairing, or 
replacing a human tissue
• Products containing or 
consisting of animal cells or 
tissues
• Products may also contain 
additional substances, 
such as cellular products, 
bio-molecules, biomaterials, 
chemical substances, 
scaffolds or matrices
• Products for cartilage or 
cardiac defects, among 
others 
• Stem cells and stem cells-
derived products
• Products containing or 
consisting exclusively of 
non-viable cells or tissues 
and which do not act 
principally by pharmacological, 
immunological, or metabolic 
actions
Combined 
ATMPs (cATMPs)
Combines:
• one or more medical 
devices within the meaning 
of or one or more active 
implantable medical 
devices and 
• its cellular or tissue part 
must contain viable cells or 
tissues, or 
• its cellular or tissue part 
containing non-viable cells 
or tissues must be liable 
to act upon the human 
body with action that can 
be considered as primary 
to that of the devices 
referred to
Therapeutic, prophylactic, or 
diagnostic effect
Regenerating, repairing, or 
replacing a human tissue
– –
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TABLE 3 | Inclusion/exclusion criteria in United States.
Cell and gene therapy products
Product category Definition Purpose Examples Exclusions
Human gene 
therapy
Administration of genetic 
material to modify or 
manipulate the expression of 
a gene product or to alter the 
biological properties of living 
cells for therapeutic use
Prevention, treatment, or cure 
of a disease or condition of 
human beings
• Plasmid DNA 
• Viral vectors
• Genetically engineered 
microorganisms
• Human gene–editing 
technology
• Patient-derived cellular gene 
therapy products
• Non-biological products (e.g., 
chemical synthetized nucleic 
acids)
• Products that are destined for 
the treatment or prophylaxis of 
infectious diseases
Somatic cell therapy Autologous, allogeneic, or 
xenogeneic cells that have 
been propagated, expanded, 
selected, pharmacologically 
treated, or otherwise altered 
in biological characteristics 
ex vivo 
Therapeutic, diagnostic, or 
preventive purposes
• Cancer vaccines
• Cellular immunotherapies
• Other types of both 
autologous and allogeneic 
cells 
• Xenogeneic living cells
• Stem cells and stem cell–
derived products
• Gene therapy–modified cells
• HCT/Ps under section 361 of 
the PHSA
Combination products
Product category Definition Purpose Examples Exclusions
Combination 
products
Two or more regulated 
components, i.e., drug, device, 
biologic as a single entity or 
packaged together, packaged 
separately but intended for use 
only with an approved individually 
specified drug, device, or 
biological product where both 
are required to achieve the 
intended use, indication, or effect 
Therapeutic, diagnostic, or 
preventive purposes
• Drug/device
• Biologic/device: cells 
combined with medical 
devices such as natural or 
synthetic scaffold
• Drug/biologic, or
• Drug/device/biologic
–
Regenerative medicine advanced therapy designation
Product category Definition Purpose Examples Exclusions
Regenerative medicine 
advanced therapy 
(RMAT)
A cell therapy, therapeutic 
tissue-engineering product, 
human cell and tissue product, 
or any combination product 
using such therapies or 
products
To treat, modify, reverse, 
or cure a serious or life-
threatening disease or 
condition; 
To address unmet medical 
needs for such disease or 
condition
• AT132 (Audentes 
Therapeutics, Inc.)
• Romyelocel-L (Cellerant 
Therapeutics, Inc.)
• AmnioFix® (MiMedx)
• CAP-1002 (Capricor 
Therapeutics) 
Products regulated solely under 
section 361 of the PHSA are 
explicitly excluded
Human cells, tissues, and cellular and tissue-based products 
Product category Definition Purpose Examples Exclusions
HCT/Ps1
Articles containing or consisting 
of human cells or tissues
Implantation, transplantation, 
infusion, or transfer into a 
human recipient
• Bone
• Ligament
• Skin
• Dura mate
• Heart valve
• Cornea
• Hematopoietic stem/
progenitor cells derived from 
peripheral and cord blood
• Manipulated autologous 
chondrocytes
• Epithelial cells on a synthetic 
matrix
• Semen or other reproductive 
tissue
• Amniotic membrane (when 
used alone (without added 
cells) for ocular repair)
• Vascularized human organs 
for transplantation
• Secreted or extracted human 
products (e.g., milk, collagen, 
and cell factors)
• Minimally manipulated bone 
marrow for homologous use 
• Ancillary products used in the 
manufacture of HCT/P
• Cells, tissues, and organs 
derived from animals other 
than humans
 In vitro diagnostic products 
1HCT/Ps that meet the criteria contemplated in 21 CFR 1721.10(a).
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of TEP, the product is administered to human beings with a 
view to regenerating, repairing, or replacing human tissue. 
The key to ascertain the most appropriate subcategory is 
based on the predominant mechanism of action of the active 
substance and the claimed intended function. A problem arises 
when the dividing line for classifying a product as SCTMPs 
or TEP is not clear. Such is the case when the product exerts 
a pharmacological action in order to regenerate, repair, or 
replace a human tissue. For these cases, premises have been 
established in order to categorize a specific product: a product 
which may fall within the definition of a TEP and SCTMP 
should be considered a TEP according to ATMP Regulation, 
although the final classification should be considered on case-
by-case basis, playing CAT’s opinion a major role. In addition, 
those products that consist of engineered or manipulated cells 
that induce regeneration, repair, or replacement in the native 
tissue via secretion of paracrine factors also fulfill the definition 
of a TEP (European Medicines Agency, 2015). Finally, it is 
considered that a TEP may contain cells or tissues of human 
or animal origin, or both, and that the cells or tissues may be 
viable or non-viable, considering viable cells those that have a 
functional cytoplasmic membrane. Two considerations in this 
regard are made: i) an inclusion criterion that automatically 
classifies a product as an ATMP applies when products contain 
or consist of animal cells or tissues and ii) an exclusion criterion 
for not classifying a potential product either as a SCTMP or TEP 
includes those products containing or consisting exclusively 
of non-viable cells or tissues and which do not act principally 
through pharmacological, immunological, or metabolic 
actions (Table 2).
As mentioned, cell- and tissue-based products can be sub-
categorized in the US regulatory framework as biologic products 
or as HCT/Ps. The definition of cell- and tissue-based products 
regulated as biologic products includes those that are “more-
than-minimally manipulated,” or for “non-homologous use,” or 
have a systemic effect, or depend on its metabolic activity (except 
for autologous cells, allogeneic cells for 1st of 2nd degree relatives 
and reproductive cells) (U.S. Department of Health and Human 
Services, 2017a). The group of advanced therapies referred to as 
“human somatic cell therapy products” fall within this definition. 
Note that, in US, there is no product class defined for tissue-based 
advanced therapies. The definition and the inclusion criteria 
for human somatic cell therapy (SCT) include the following 
(U.S. Department of Health and Human Services, 1993; U.S. 
Department of Health and Human Services, 1998): i) SCT 
consists of administration to humans of autologous, allogeneic, 
or xenogeneic living cells; ii) the manufacture of products for 
SCT involves the ex vivo propagation, expansion, selection or 
pharmacologic treatment of cells, or other alterations of their 
biological characteristics, and therefore considered “more-than-
minimally manipulated”; and iii) the aim of this cellular products 
is to be used for therapeutic, diagnostic, or preventive purposes 
(Table 3).
Therefore, the categorization or classification of human cells 
and tissue products between the EU and the US is different. On 
one hand, in the EU, there is a differentiation between products 
considered TEP, or SCTMP, in which the difference lies in the 
claimed indication, while in the US, cell and tissue products 
that constitute an advanced therapy will be labeled under the 
SCT’s term. For instance, MACI (matrix-applied characterized 
autologous cultured chondrocytes) is a product approved both in 
EU and US which consists of autologous chondrocytes seeded on 
a collagen membrane of porcine origin indicated for the repair 
of symptomatic, full-thickness cartilage defects of the knee in 
adult patients. While in US, MACI is considered a cell therapy, a 
biologic-device combination product with the aim of being used 
for therapeutic purposes; in EU, it is classified as combined TEP, 
since the claimed primary mechanism of action of the product 
is the regeneration, repair, and replacement actions (European 
Medicines Agency, 2018d; U.S. Food and Drug Administration, 
2018i). Finally, the FDA classifies xenogeneic living cells as SCT, 
as well as in EU, where these therapies can be assumed to be 
automatically classified as ATMPs from a regulatory point of 
view (European Medicines Agency, 2009; Schuurman, 2015).
Manipulation and Homologous Use
Both aforementioned inclusion criteria, manipulation and 
homologous use, have their own definitions depending on the 
region. In EU, “substantial manipulation” means to modify 
the biological characteristics, physiological functions, or 
structural properties relevant for the intended clinical use. For 
instance, cell separation, concentration, or purification does 
not represent a substantial manipulation if the cells performed 
the same biological activity as in the human body, whereas cell-
culturing leading to expansion or cell activation with growth 
factors does. A non-exhaustive list of manipulations that is 
not considered substantial for ATMP purposes is provided in 
Annex I of Regulation EC (No). 1394/2007 and includes: cutting, 
grinding, shaping, centrifugation, soaking in antibiotic or 
antimicrobial solutions, sterilization, irradiation, cell separation, 
concentration, or purification, filtration, lyophilization, freezing, 
and cryopreservation. On the other hand, the “same essential 
function” (or homologous use) means that the cells or tissues 
(whether substantially manipulated or not) are used to maintain 
the original function(s) in the same anatomical or histological 
environment. By contrast, “different essential function” (or non-
homologous use) for cells or tissues (substantially manipulated 
or not) are those not intended to be used for the same essential 
function(s) in the recipient as the original cell/tissue would 
perform in the donor (European Medicines Agency, 2015). 
Allogeneic human islets of Langerhans for the treatment of severe 
forms of type 1 diabetes is a common example of cell/tissue 
products that might be regarded as non-ATMPs, since these cells/
tissues might be isolated, purified, and cultured by methods that 
do not result in a modification of the biological characteristics 
and are re-administered to fulfill their same essential function. 
In 2011, CAT considered that autologous/allogeneic human 
islets of Langerhans were not an ATMP (European Medicines 
Agency, 2011b), but are considered to fall under the provisions 
of the Tissues and Cells legislation. Under this legislation, these 
cells are neither considered a medicinal product, since the active 
substance, i.e., human tissues, cannot be commercialized or 
manufactured on an industrial scale for ethical and legal reasons. 
However, in 2013, a product that consists of viable alginate 
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encapsulated porcine pancreatic islet cells was classified as a 
SCTMP (European Medicines Agency, 2013b). In this case, the 
porcine islets were isolated from pancreases of neonatal piglets 
and cultured during 30 days, in which cell differentiation occurs 
by increasing the amount of insulin released from the cells, this 
being considered a substantial manipulation. Nevertheless, it 
should be noted that, since this product is based on xenogeneic 
cells, it is automatically considered an ATMP, as previously 
discussed. Finally, in 2018, the CAT considered an encapsulated 
allogeneic pancreatic islet–based product a non-ATMP. The 
consideration here is whether or not the encapsulation itself 
might change the characteristics of the islet (European Medicines 
Agency, 2018e).
In US, the definitions of manipulation and homologous use 
are defined for HCT/Ps, and by exclusion, the products based on 
cells and tissues that do not comply with these criteria established 
for a HTC/Ps could be considered a biological product, and 
consequently, an advanced therapy (U.S. Department of Health and 
Human Services, 2017a). The criteria for HCT/Ps include “minimal 
manipulation” and “homologous use,” while “more-than-minimally 
manipulated” and “non-homologous use” are considered for cell- 
and tissue-based products considered as biological drugs.
Unlike the EU, in the US, there is a differential definition of 
minimal manipulation depending on whether or not the product 
consists of structural tissue. “Minimal manipulation” is defined as: 
“processing that does not alter the original relevant characteristics 
of the tissue relating to the tissue’s utility for reconstruction, repair, 
or replacement” for structural tissues, and “processing that does 
not alter the relevant biological characteristics of cells or tissues” 
for cells or non-structural tissues (U.S. Code of Federal Regulation 
Title 21, 2018a). For clarification, structural tissue is defined as 
human cells/tissues that physically support or serve as a barrier or 
conduit, or connect, cover, or cushion (e.g., amniotic membrane 
and umbilical cord). On the other hand, human cells/tissues that 
serve as metabolic or other biochemical roles in the body, such as 
hematopoietic, immune, and endocrine functions, are generally 
considered cells/non-structural tissues (e.g., hematopoietic stem/
progenitor cells). It is considered that this differentiation between 
structural and non-structural tissues is required, since structural 
HCT/Ps generally raise different safety and efficacy concerns from 
those of cells or non-structural tissues.
As a result, the term “processing” is defined as any activity 
performed on a cell- and/or tissue-based product other than 
recovery, donor screening, donor testing, storage, labeling, 
packaging, or distribution, such as testing for microorganisms, 
preparation, sterilization, steps to inactivate or remove 
adventitious agents, preservation for storage, and removal from 
storage. Processing includes cutting, grinding, shaping, culturing, 
enzymatic digestion, and decellularization (U.S. Code of Federal 
Regulation Title 21, 2018a). Cell expansion, encapsulation, 
activation, or genetic modification are considered to be more 
than minimal manipulations. The aforementioned or any other 
additional processing steps should be considered in determining 
whether a product is minimally manipulated or not.
For products that contain structural tissues, “original relevant 
characteristics of structural tissues” generally comprise the 
properties of that tissue in the donor that contribute to the 
tissue’s function or functions; for instance, the original relevant 
characteristics of amniotic membrane generally include the 
physical integrity, tensile strength, and elasticity of the tissue. 
Following with the same example, preserving and packaging 
amniotic membrane in sheets would be considered a minimal 
manipulation, yet more than minimally manipulated if the 
amniotic membrane is grounded, lyophilized, and packaged as 
particles, since it would imply the separation of structural tissue 
into components whose characteristics related to serving as a 
barrier are altered. However, ground bone adhered to form bone 
particles would generally be considered minimally manipulated 
since it can maintain its utility as a supporting structure. For 
products that contain cells (both structural and non-structural) 
and non-structural tissues, “original relevant characteristics” 
include differentiation and activation state, proliferation 
potential, and metabolic activity, e.g., for hematopoietic stem/
progenitor cells, the ability to repopulate the bone marrow by 
self-renewal and by differentiating along myeloid and lymphoid 
cell lines. In this case, cell selection on peripheral blood apheresis 
products to obtain a higher concentration of hematopoietic 
stem/progenitor cells for transplantation would be considered 
a minimal manipulation, whereas differentiating the cells by 
culturing under specific conditions would be considered more 
than a minimal manipulation because the characteristics of 
multipotency and capacity for self-renewal are altered. The 
storage of the product should also be considered, since it can 
alter the original relevant characteristics of the cells and tissues. 
If a product is stored in a buffer solution or is cryopreserved, it 
would generally meet the minimal manipulation criterion.
Regarding “homologous use,” there is also a differentiation 
between structural and non-structural tissues. The term of 
homologous use for a structural tissue defines that the tissue is 
intended to be used for a homologous function when used to 
replace an analogous structural tissue that has been damaged or 
otherwise does not function adequately. Therefore, it is defined as 
the repair, reconstruction, replacement, or supplementation of a 
recipient’s cells or tissues with an HCT/P that performs the same 
basic function or functions in the recipient as in the donor (U.S. 
Code of Federal Regulation Title 21, 2018a). The Agency would 
consider structural tissue to be performing a non-homologous 
function when used for a purpose different from those that it 
fulfils in its native state, or in a location of the body, where such 
structural function does not normally occur. Similarly, cellular 
products are considered to be used for a homologous function 
when they are used to perform their native function, and for a 
non-homologous function when they are used to perform other 
functions (U.S. Department of Health and Human Services, 
2017a; U.S. Department of Health and Human Services, 2017b).
As it has been discussed, it is important to have a product 
defined since, otherwise, the legal requirements for these could 
be violated. In the US, this was the case of some amniotic-/
chorionic-based products, used for wound healing, which 
were considered HCT/Ps by some companies, when in fact, 
they were biological products. These products were therefore 
launched to the market without a premarket review, and after 
an inspection of the CBER Office of Compliance and Biologics 
Quality, an appropriate clinical development was requested in 
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order to demonstrate the safety and efficacy of the intended use 
of the product, as well as distribution of the product to test its 
clinical use in humans after IND application, and the subsequent 
submission of a BLA approval for its marketing. This implied 
that the cost of bringing this product to the market was very 
different from the one initially invested, given that the preclinical 
and clinical developments are much broader than for an HCT/Ps 
(U.S. Food and Drug Administration, 2018j; U.S. Food and Drug 
Administration, 2018k).
Therefore, both in the EU and in the US, in order to 
consider a cell- and tissue-based products advanced therapies, 
it must be ascertained that the processing of the cells implies a 
manipulation that alters their biological characteristics. In EU, 
the concept is referred as a “substantial manipulation,” while 
in US, it is referred as “more-than-minimally manipulated.” 
Regarding this term of manipulation in US, there is a nuance that 
differs from EU definitions and consists in the differentiation 
of structural and cells/non-structural tissues in the US. The 
European definitions of substantial manipulation and non-
homologous use would encompass both structural and non-
structural tissues under the same definition. Regardless of the 
examples of processing mentioned for either regions, for both, 
it is key to determine if the processing changes the original 
characteristics of the product. This requires a characterization 
of the product during the manufacturing process, as a part of 
development, to corroborate whether or not the phenotypic and 
physiological characteristics of a potential product have been 
altered. On the other hand, the European terminology uses the 
term “engineered” to denominate those cells or tissues that are 
substantially manipulated and/or used for a different essential 
function (or non-homologous use), which is mandatory 
criteria to classify a product as an advanced therapy. In the US, 
the term of non-homologous use is not explicitly mentioned 
in the definition of SCT, although it is to classify a product 
as biologic in the general definition of cell- and tissue-based 
products. Note that the nomenclature of “non-homologous use” 
is be common for both regions, although in Europe, the term 
“different essential function” would also be the one harmonized 
according to the EMA guidelines. All these mentioned 
differences in terminology can be important when submitting 
documents to the respective Agencies, since it is advisable to 
use the specific terminology used in each region (Table 4).
Combined Advanced Therapy Medicinal 
Products
In EU, there is a specific category for those products that consist 
in an ATMP combined with a medical device. A medical device 
is defined as any instrument, apparatus, appliance, material, or 
other article intended by the manufacturer to be used on human 
beings for the purpose of: i) diagnosis, prevention, monitoring, 
treatment or alleviation of disease, compensation for an injury 
or handicap, investigation, replacement, or modification of the 
anatomy of a physiological process, or control of conception 
and ii) which does not achieve its principal intended action 
in or on the human body by pharmacological, immunological, 
or metabolic means, but may assist its function by such 
means (European Union, 2017). Examples of medical devices 
in cATMP could be scaffolds, matrices, and encapsulation 
systems for cells, such as microspheres, among others. The 
criteria to meet in this category class are that the product 
must incorporate, as an integral part of the product, one or 
more medical devices. The medical device should be used in 
the combination, in the same way as its intended use without 
additional components. On the other hand, the cellular or 
tissue part of the product must contain viable cells or tissues, 
or if containing non-viable cells or tissues, it must be liable to 
act upon the human body with actions that can be considered 
primary to those of the devices referred to (European 
Medicines Agency, 2015).
In US, there is no specific category for cATMPs, but there 
are nine different types of combined products including drug/
device, biologic/device, drug/biologic, or drug/device/biologic. 
The definition takes into account how the product is packaged, 
i.e., together in a single package or packaged separately, 
and if all components of the product are needed to achieve 
the intended use, indication, or effect. Among all of these 
categories, the type-5 combination product named “device 
coated or otherwise combined with biologic” constitutes the 
biologic/device combination where the device has an additional 
function in addition to delivering the drug and constitutes an 
“integral part” of the final product, e.g., live cells seeded on 
or in a device scaffold (U.S. Food and Drug Administration, 
2018a). In US, a medical device is defined as an instrument, 
apparatus, implement, machine, contrivance, implant, in 
vitro reagent, or other similar or related article, including any 
component, part, or accessory, which has at least one of the 
following three characteristics: i) it is recognized in the official 
National Formulary or the United States Pharmacopeia, or any 
supplement to them; ii) it is intended for use in the diagnosis, 
cure, mitigation, treatment, or prevention of a disease; or 
iii) is intended to affect the structure or any function of the 
human body or other animals and does not achieve its primary 
intended purposes through chemical action within or on the 
human body or other animals and which does not depend on 
being metabolized for the achievement of its primary intended 
purposes (U.S. Code of Federal Regulation Title 21, 2018b; U.S. 
Food and Drug Administration, 2018l).
Therefore, while in EU, cATMPs are the fourth subcategory 
of products within the group of advanced therapies; in the 
US, the subcategory defined for combined products is very 
broad and includes drugs, biological, and medical devices. 
The category of type-5 combined products would constitute 
a group equivalent to what defines cATMPs in the US, where 
the product is a single-entity combination product, or the 
device constitutes “an integral part of the product” according to 
European definition. For both EU and US, the final combined 
product will be a biological and a medical device, where the 
definitions of medical device are equivalent: the medical device 
assists in the primary function of the biological component. 
Following MACI’s aforementioned example, for both regions, 
the porcine collagen membrane is considered a device 
constituent of the product a CE-marked class III device in EU 
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(European Medicines Agency, 2018d; U.S. Food and Drug 
Administration, 2018i).
The fact of combining a biological product with a medical 
product complicates its development, and in US, unlike in 
EU, there are guidances with some considerations to be taken 
into account during the development of these products (U.S. 
Food and Drug Administration, 2006; U.S. Food and Drug 
Administration, 2019d).
GENERAL DISCUSSION AND 
CONCLUSION
Our analysis reveals a difference between EU and US in the 
sub-categorization of advanced therapies and the regulatory 
terminology defining them. The criteria that must be met in 
both the EU and the US in order to classify a product as an 
advanced therapy is similar, although EU presents a more precise 
TABLE 4 | Terminology and definitions for cell- and tissue-based products as advanced therapies.
European Union1 United States2
Term Definition Term Definition
Substantial 
manipulation
Biological characteristics, physiological functions, 
or structural properties have been modified to 
be relevant for their intended function during the 
manufacturing process.
More than “minimally 
manipulated”*
For structural tissue, processing that alters the original 
relevant characteristics of the tissue relating to the tissue’s 
utility for reconstruction, repair, or replacement
For cells or non-structural tissues, processing that alters the 
relevant biological characteristics of cells or tissues
Different 
essential 
function or non-
homologous use
Cells when removed from their original 
environment in the human body are not used 
to maintain the original function(s) in the same 
anatomical or histological environment.
Non-homologous use Homologous use means the repair, reconstruction, 
replacement, or supplementation of a recipient’s cells or 
tissues with an HCT/P that performs the same basic function 
or functions in the recipient as in the donor, including when 
such cells or tissues are for autologous use.
Basic functions of a structural tissue would generally be 
to perform a structural function for example, to physically 
support or serve as a barrier or conduit, or connect, cover, 
or cushion. 
Basic functions of a cellular or nonstructural tissue would 
generally be a metabolic or biochemical function, such as 
hematopoietic, immune, and endocrine functions.
Manufacturing Defined to include all operations of receipt of 
materials, production, packaging, repackaging, 
labeling, relabeling, quality control, release, 
storage, and distribution of active substance(s) 
and the related controls
Processing Any activity performed on an cell- and/or tissue-based 
product, other than recovery, donor screening, donor testing, 
storage, labeling, packaging, or distribution, such as testing 
for microorganisms, preparation, sterilization, steps to 
inactivate or remove adventitious agents, preservation for 
storage, and removal from storage
List of 
manipulations
Provided in Annex I of Regulation EC (No.) 
1394/2007
List of processing Provided in regulatory considerations for human cells, 
tissues, and cellular and tissue-based products: minimal 
manipulation and homologous use (2017) and proposed 
approach to regulation of cellular and tissue-based products 
(1997), and the United States pharmacopoeia (cellular and 
tissue-based products: 1046)
– – Original relevant 
characteristics
For products that contain structural tissues, “original relevant 
characteristics of structural tissues” generally include the 
properties of that tissue in the donor that contribute to the 
tissue’s function or functions.
For products that contain cells (both structural and non-
structural) and non-structural tissues, “original relevant 
characteristics” include differentiation and activation state, 
proliferation potential, and metabolic activity.
Viable cell A viable cell is a cell that has a functional 
cytoplasmic membrane. 
(The European Pharmacopoeia provides 
information on assays to demonstrate 
cytoplasmic membrane integrity and activity 
< 20729 >.)
Living cells –
(The United States pharmacopoeia cellular and tissue-based 
products <1046>)
Tissues Defined in Directive 2004/23/EC (Art 3.b) as “all 
constituent parts of a human body formed by 
cells.”
– –
1Definitions provided in EMA/CAT/600280/2010 Rev.1, CPMP/ICH/4106/00 and Regulation EC (No) 1394/2007; 2Definitions provided in the Code of Federal Regulation (21 CFR 
1271.3; 21 CFR 1271.10), Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use (2017) and 
Proposed approach to regulation of cellular and tissue-based products (1997); *The definition provided is minimal manipulation. For advanced therapies the term that applies is 
“more than minimally manipulated”.
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sub-classification with more defined inclusion criteria between 
these subcategories. The criteria to determine if a product qualifies 
as a gene therapy may be simpler or more obvious than for cell 
therapies, although there are some relevant considerations for all 
defined subcategories of advanced therapies that can change the 
classification of the product both in EU and US.
EU and US are facing similar challenges regarding the 
regulation of ATMPs due to their inexperience in this specific 
medicinal product group, and because Europe covers a variety of 
overlaying jurisdictions and authorities on a member state level 
(Bender, 2018; Ten Ham et al., 2018). European and American 
legislation and regulatory guidelines launched by EMA and FDA 
show similarities and differences in the ATMP classification for 
both regions. It is unknown if these differences can be translated 
into divergent final recommendations by the regulatory 
authorities. Currently, the number and type of ATMPs approved 
differ between the two regulatory Agencies. In EU, up to 12 
ATMPs have been authorized from 2009, but four of them have 
been withdrawn throughout the past 10 years. In US, nine gene 
and cell therapies haven’t been authorized, and only six of them 
match in the two Agencies. The rationale behind these differences 
is unknown, but it seems feasible that a worldwide harmonization 
of the procedures involved in the development of ATMPs may 
allow to reach similar ultimate decisions. It is acknowledged that 
EMA and FDA have been collaborating for the past 15 years 
with the aim to ameliorate regulatory excellence. An ATMP 
cluster has been created under the umbrella of the reinforced 
EU/US collaboration on medicines with the aim to facilitate 
regulatory excellence of the new medicinal products (European 
Medicines Agency, 2018f). Yet, Agencies’ recommendations 
are evolving and being updated over time in a non-parallel 
manner. In 2018, the FDA launched several guidances that 
include specific recommendations for the development of 
ATMPs aimed at certain types of diseases such as hemophilia or 
retinal disorders (U.S. Food and Drug Administration, 2019e), 
while the EMA guidelines published to date are more generalist, 
encompassing only the development of ATMPs according to the 
three main groups of therapies, GTMP, SCTMP, and TEP. In the 
future, it would be convenient to begin a progressive process of 
convergence between both Agencies in terms of terminology, 
legal recommendations, and characterization requirements. In 
this regard, some steps could be taken to reach this alignment 
between regulators—for example, common guidelines, increased 
number of EMA/FDA parallel scientific advice from the 
beginning of the lifecycle of the medicinal product, as well as 
similar post-authorization monitoring of the products or real-
world evidence data generation.
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